[Characterization and biological significance of peripheral blood dendritic cell subsets in patients with severe burn].
OBJECTIVE
To investigate the characteristics of dendritic cells (DCs) in patients with severe burn.


METHODS
Peripheral blood samples were obtained from 12 patients with severe burn 1, 2, 3, and 4 weeks after burn, and from 10 healthy donors as controls. Mononuclear cells were isolated, and GM-CSF 1000 and IL-4 were used to induce the transformation of DCs. Mature DCs were harvested and underwent flow cytometry to detect the expression of HLA-DR, CD80, CD83, CD86, CD14, and CD11c.


RESULTS
1, 2, 3, and 4 weeks after burn, the expression levels of HLA-DR were 62.1% +/- 8.4%, 65.0% +/- 6.2%, 68.4% +/- 5.7%, and 75.4% +/- 8.4% respectively; the expression levels of CD80 were 12.9% +/- 3.7%, 14.7% +/- 2.5%, 16.1% +/- 4.2%, and 16.2% +/- 4.8%; the expression levels of CD83 were 15.1% +/- 4.2%, 15.1% +/- 4.0%, 22.2% +/- 7.7%, and 21.3% +/- 7.0% respectively; the expression levels of CD86 were 69.2% +/- 7.1%, 70.5% +/- 5.4%, 75.1% +/- 6.1%, and 79.6% +/- 6.4% respectively, all significantly lower than that of the control group (84.3% +/- 8.2%, all P < 0.001). 1, 2, 3, and 4 weeks after burn, the expression levels of CD14 in the DCs of the severe burn patients were 12.7% +/- 1.9%, 12.0% +/- 1.5%, 11.3% +/- 1.3%, and 9.3% +/- 1.7% respectively, all significantly higher than that of the control group (7.3% +/- 1.5%, P < 0.001). 1, 2, 3, and 4 weeks after burn, the expression levels of CD11c in the DCs of the severe burn patients were 86.8% +/- 6.1%, 89.5% +/- 5.1%, 91.3% +/- 2.8%, and 89.4% +/- 4.0% respectively, a little lower than that of the control group, however, without significant difference (92.6% +/- 3.8%, P > 0.05).


CONCLUSIONS
The functions of DCs in the patients with severe burn are declined, which may partly contribute to infection after burn.
Zhang
Pu-Zhu
PZ
Burn Department, Beijing Jishuitan Hospital, Beijing 100035, China.
Qin
Feng-Jun
FJ
Ma
Chun-Xu
CX
Su
Hong
H
Yu
Dong-Ning
DN
Li
Chi
C
D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000096:biosynthesis; D018952:Antigens, CD34 / Q000096:biosynthesis; D018122:B7-1 Antigen / Q000096:biosynthesis; D051940:B7-2 Antigen / Q000096:biosynthesis; D002056:Burns / Q000097:blood* / Q000276:immunology* / Q000473:pathology; D039521:CD11c Antigen / Q000096:biosynthesis; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000378:metabolism*; D005260:Female; D005434:Flow Cytometry; D006684:HLA-DR Antigens / Q000096:biosynthesis; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis; D018950:Lipopolysaccharide Receptors / Q000096:biosynthesis; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis; D008875:Middle Aged; D000097802:CD83 Antigen
D015703:Antigens, CD; D018952:Antigens, CD34; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D039521:CD11c Antigen; D006684:HLA-DR Antigens; D007136:Immunoglobulins; D018950:Lipopolysaccharide Receptors; D008562:Membrane Glycoproteins; D000097802:CD83 Antigen